Enanta Pharmaceuticals Inc. Watch

from 10-K 4 pages Third Amendment to Lease Agreement

from 10-K 5 pages Second Amendment to Lease Agreement

from 10-K 6 pages Enanta Pharmaceuticals, Inc. 2024 Inducement Stock Incentive Plan Relative Total Stockholder Return Unit Certificate

from 10-K 4 pages Enanta Pharmaceuticals, Inc. 2024 Inducement Stock Incentive Plan Performance Share Unit Certificate

from 10-K 4 pages Enanta Pharmaceuticals, Inc. Restricted Stock Unit Grant Notice and Award Agreement

from 10-K 4 pages Enanta Pharmaceuticals, Inc. Nonstatutory Stock Option Grant Notice and Agreement

from 10-Q 5 pages Amended and Restated Employment Agreement

from 8-K 12 pages Enanta Pharmaceuticals, Inc. 2019 Equity Incentive Plan

from 8-K 50 pages Certain Identified Information Has Been Omitted From This Exhibit Because It Is (I) Not Material and (II) of the Type That the Registrant Treats as Private or Confidential. [***] Indicates That Information Has Been Omitted. Royalty Purchase Agreement Between Enanta Pharmaceuticals, Inc. and Ocm Life Sciences Portfolio LP Dated as of April 25, 2023

from 8-K 14 pages Enanta Pharmaceuticals, Inc. 2019 Equity Incentive Plan

from 8-K 93 pages Lease Agreement

from 8-K 34 pages First Amendment to Lease Agreement

from 8-K 4 pages Second Amendment to Lease

from 10-Q 9 pages Consulting Agreement

from 8-K 12 pages Enanta Pharmaceuticals, Inc. 2019 Equity Incentive Plan

from 10-K 9 pages Consulting Agreement

from 8-K 16 pages Enanta Pharmaceuticals, Inc. 2019 Equity Incentive Plan

from 8-K 12 pages Third Amendment to the Collaborative Development and License Agreement

from 8-K 175 pages 1. Definitions1 2. Administration of the Research Program, Development Program and Commercialization18 2.1 Joint Steering Committee18 2.2 Affiance Managers21 2.3 Joint Co-Development and Commercialization Committee21 3. Research Program24 3.1 Objectives of the Research Program24 3.2 Research Plan24 3.3 Conduct of Research Program24 3.4 Records25 3.5 Reports25 3.6 Selection of Candidates25 3.7 Supply of Proprietary Materials26 3.8 Research Program Term26 4. Development and Commercialization26 4.1 Development of Candidates26 4.2 Commercialization of Products27 4.3 Development and Commercialization Diligence28 4.4 Compliance28 4.5 Reports; Information; Updates28 4.6 Product Recalls30 4.7 Product Labeling30 5. Co-Development and Profit Share Option30 5.1 Exercise of Co-Development and Profit Share Option30 5.2 Effect of Exercise30 5.3 Reconciliation and Auditing of Development Costs31 5.4 Allocation of Shared Clinical Trial Costs32 5.5 Roll-Over Payments32 Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. B4915206.2

from 10-K 3 pages Form of Notice of Restricted Stock Unit Award Under 2019 Equity Incentive Plan